A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Phase 2 Not yet recruiting 250 enrolled Caliway Biopharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.

Timeline

Start: 2027-02
Primary completion: 2028-02
Completion: 2028-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CBL-514	Unknown	120 ml	Subcutaneous

Indications

No indication recorded.